مباشر
FierceBiotechDespite data concerns, Roche’s oral SERD can still be largest product in company history: execFierceBiotechRegeneron ushers in new genetic medicine era with groundbreaking gene therapy approvalThermo FisherThermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business JournalsAgilentEarnings snapshot: Agilent Technologies misses FQ1 estimates; gives FQ2 and raises FY26 outlook, above forecast - MSN10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - TradingViewFierceBiotechKurma closes €215M Europe-focused fund to spread across 20 biotechsFierceBiotechPfizer cans work on next-gen conjugate in cancer patientsBioWorldAnglonordic panelists discuss how to get the most from AIThermo FisherThermo Fisher falls after earnings top estimates, but growth concerns persist - Yahoo FinanceThermo FisherThermo Fisher (TMO) Q1 2026 Earnings Transcript - The Motley FoolLonza NewsBanks kick off talks on Lone Star’s $1.75 billion Lonza unit debt - Bloomberg News - TradingViewPLoS BiologySea urchin eggs contain a plastid-derived structure that contributes to their development
Endpoints News ١٢ يناير ٢٠٢٦

Eisai licenses Nuvation lung cancer pill; Alnylam's stock dips after sales data report

Eisai licenses Nuvation lung cancer pill; Alnylam's stock dips after sales data report

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.